Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K243412
    Date Cleared
    2025-07-16

    (257 days)

    Product Code
    Regulation Number
    876.5010
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    ARCHIMEDES Biodegradable Pancreatic Stent

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The ARCHIMEDES biodegradable pancreatic stent is intended to drain pancreatic ducts in patients indicated for pancreatic duct stenting.

    The ARCHIMEDES Biodegradable Pancreatic Stent is intended to be delivered through the working channel of a therapeutic endoscope using a guidewire with a maximum outer diameter of 0.035 inches and a pushing catheter of between 5 to 10 French.

    Device Description

    The ARCHIMEDES™ Biodegradable Pancreatic Stent is a single use, sterile, biodegradable stent implant intended for use in the pancreatic duct. The device is intended to be delivered endoscopically through the working channel of a duodenoscope.

    The ARCHIMEDES™ has a fluted cross-sectional profile and provides three drainage channels, two of which spiral in a double helical pattern down the length of the stent and one of which is the hollow inner lumen of the device tube. This unique design permits fluids to flow both around and through the stent. It has a curved form design to fit the natural curvature of the pancreatic duct, and contains flap and split-end features to minimize spontaneous migration of the stent while in situ. The tips of the stent are tapered to facilitate atraumatic insertion through the papilla. The stent is visible under fluoroscopy. The 8F and 10F stent design contains flaps on each end. The 6F stent design has a flap on one end and a split-end feature on the other end.

    The stent is offered in outer diameters of 2.0mm (6F), 2.6mm (8F), or 3.4mm (10F), and in various lengths to accommodate variations in pancreatic anatomy across individuals (40, 60, 80, 100, 125, 150, 175, 200, and 225 mm). The ARCHIMEDES™ is designed to be an alternative to plastic stents that maintains the same clinical purpose. In particular, it is used in a manner similar to current FDA-cleared plastic pancreatic stents. The primary difference is that the ARCHIMEDES™ biodegrades in-situ rather than requiring an additional procedure for removal needed of plastic stents.

    The Minimal Strength Retention (MSR) time for the material - i.e., the minimum amount of time for which the device retains at least 10% of an initial strength parameter and remains intact with no breaks is 12 days. Full-degradation or no stent presence is reached within

    AI/ML Overview

    The provided FDA 510(k) clearance letter and summary for the ARCHIMEDES™ Biodegradable Pancreatic Stent do not contain the specific acceptance criteria and detailed performance results for the device. While it states that "All tests met required acceptance criteria," the actual criteria and reported numerical performance are not explicitly listed.

    Furthermore, the document alludes to "eight clinical studies" but provides no details whatsoever about their methodology, sample sizes, data provenance, expert qualifications, adjudication methods, or specific outcomes. It's a high-level statement without any actionable data.

    Therefore, many of your requested fields cannot be filled from the provided text.

    Here's a breakdown of what can be extracted and what cannot, based on the input:

    1. A table of acceptance criteria and the reported device performance

    Acceptance CriteriaReported Device Performance
    Non-clinical Performance
    Visual InspectionMet required acceptance criteria (no specific details provided)
    Outer diameter, LengthMet required acceptance criteria (no specific details provided)
    Stent Swelling CharacterizationMet required acceptance criteria (no specific details provided)
    Flow RateMet required acceptance criteria (no specific details provided)
    Inherent ViscosityMet required acceptance criteria (no specific details provided)
    Guidewire CompatibilityMet required acceptance criteria (no specific details provided)
    Endoscope CompatibilityMet required acceptance criteria (no specific details provided)
    Introducer Sleeve CompatibilityMet required acceptance criteria (no specific details provided)
    Simulated UseMet required acceptance criteria (no specific details provided)
    TrackabilityMet required acceptance criteria (no specific details provided)
    PushabilityMet required acceptance criteria (no specific details provided)
    Flexibility/Kink ResistanceMet required acceptance criteria (no specific details provided)
    Retraction ForceMet required acceptance criteria (no specific details provided)
    Tensile StrengthMet required acceptance criteria (no specific details provided)
    Fluoroscopic VisibilityMet required acceptance criteria (no specific details provided)
    DegradationMet required acceptance criteria (no specific details provided)
    Biocompatibility (per ISO 10993-1:2009)
    MEM Elution CytotoxicityMet required acceptance criteria (no specific details provided)
    ImplantationMet required acceptance criteria (no specific details provided)
    Guinea Pig Maximization SensitizationMet required acceptance criteria (no specific details provided)
    28 Day Dual Route IV/IP Systemic ToxicityMet required acceptance criteria (no specific details provided)
    Acute Systemic InjectionMet required acceptance criteria (no specific details provided)
    Intracutaneous ReactivityMet required acceptance criteria (no specific details provided)
    Material Mediated PyrogenMet required acceptance criteria (no specific details provided)
    Chemical Extractables Studies & Toxicological Risk AssessmentMet FDA's Guidance document (no specific details provided)
    Sterilization (per ISO 11135-1)Met Sterilization requirements (no specific details provided)
    Ethylene Oxide Sterilization Residuals (per ISO 10993-7)Met Ethylene Oxide Sterilization Residuals requirements (no specific details provided)
    Minimal Strength Retention (MSR)The device retains at least 10% of an initial strength parameter and remains intact with no breaks for 12 days.
    Full DegradationFull-degradation or no stent presence is reached within
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1